Citokine status in pathients with recurrent urinary tract infection

Volkova E.V., Homenkov V.G., Ahmatova E.A., Chalaya E.L., Sorokina E.V., Ahmatova N.K., Perepanova T.S.

The goal: to study the influence of the drug the "Uro-Vaksom®" on cytokine status of patients with recurrent bacterial cystitis.

Materials and methods: 66 women, including 40 women with recurrent infections of the lower urinary tract at the age of 18 to 68 years. Patients underwent monotherapy UroVaksom®® (URO-VAXOM®), (Astellas Pharma Europe BV, Netherlands), which is a freeze-dried bacterial lysate 18 strains of Escherichia coli, according to the scheme into one capsule daily (6 mg) for 90 consecutive days (3 months). Prior to treatment, at 1, 3, and at 6 months for all patients was conducted bacteriological analysis urine levels were studied in serum and urinary tract mucous proand anti-inflammatory cytokines IL-1b, IL-2, TNF-α, IFN-g, IL-12p70, IL-4, IL-5, IL-6, IL-10, IL-13, IL-9, Il-17a, IL-22 was determined by flow cytometry (Sytomix FC-500, Beckman Coulter, USA) c using the test system Multiplex-13 (Bender MedSystems, Austria). Analysis of the results was performed using Statistica program 10.

Results: to recurrent infections of the lower urinary tract characterized by low levels of IL-2, IFN-γ, IL-12p70 in the serum and increased concentrations of TNF-α and IL-1β. Use of the drug Uro-Vaksom immunocorrecting has little effect on Th1 / Th2 type cytokines and substantially corrects the balance of the system Th9, Th17 and Th22 types of cytokines in patients with recurrent infections of the lower urinary tract.

AttachmentSize
Download1.34 MB
chronic recurrent cystitis in women, cytokine status, treatment, Uro-Vaхom